Pharmaceutical firm Novo Nordisk’s sales growth has accelarated since 2019, when it introduced new financial targets and ambitions for 2025. A theme of the company’s capital markets day, which is taking place at the time of writing on Thursday, is how to continue on this track.
”We are very encouraged by the growth momentum we have now. Today, we will try to explain how we believe we can maintain that growth and how we can drive growth within diabetes and obesity (two of Novo’s business areas, ed.) by maximizing semaglutide’s potential in the short and medium term,” says Novo Nordisk CEO Lars Fruergaard Jørgensen at the meeting.